"EvoVax" - A rationally designed inactivated Salmonella Typhimurium vaccine induces strong and long-lasting immune responses in pigs

Vaccine. 2023 Aug 31;41(38):5545-5552. doi: 10.1016/j.vaccine.2023.07.059. Epub 2023 Jul 28.

Abstract

Salmonella enterica subspecies enterica serovar Typhimurium (S.Tm) poses a considerable threat to public health due to its zoonotic potential. Human infections are mostly foodborne, and pork and pork products are ranked among the top culprits for transmission. In addition, the high percentage of antibiotic resistance, especially in monophasic S.Tm, limits treatment options when needed. Better S.Tm control would therefore be of benefit both for farm animals and for safety of the human food chain. A promising pre-harvest intervention is vaccination. In this study we tested safety and immunogenicity of an oral inactivated S.Tm vaccine, which has been recently shown to generate an "evolutionary trap" and to massively reduce S.Tm colonization and transmission in mice. We show that this vaccine is highly immunogenic and safe in post-weaning pigs and that administration of a single oral dose results in a strong and long-lasting serum IgG response. This has several advantages over existing - mainly live - vaccines against S.Tm, both in improved seroconversion and reduced risk of vaccine-strain persistence and reversion to virulence.

Keywords: EvoVax; Evolutionary trap; Oral vaccine; Salmonella; Swine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibody Formation
  • Humans
  • Mice
  • Salmonella Infections, Animal* / prevention & control
  • Salmonella Vaccines*
  • Salmonella typhimurium
  • Swine
  • Swine Diseases* / prevention & control
  • Vaccines, Attenuated
  • Vaccines, Inactivated

Substances

  • Vaccines, Inactivated
  • Salmonella Vaccines
  • Vaccines, Attenuated